Lymphedema denials in California external review
In the California DMHC record, independent physician reviewers decided 89 published external-review cases involving lymphedemaand overturned the plan’s denial in 60.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for lymphedema
| Category | Decisions | Overturned |
|---|---|---|
| Flexitouch Pneumatic Compression Device | 8 | 37.5% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 60 | 50% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 29 | 82.8% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Flexitouch pneumatic compression pump. Pneumatic compression devices may be used at home as part of self-care. In a one-year trial of Flexitouch advanced pneumatic compression devices in 74 different patients with phlebolymphedema or lymphedema secondary to chronic venous insufficiency, researchers found that while an improvement in quality of life was not demonstrated at 12 weeks, there were steady and sustained benefits at one year. A researcher reports that a panel of experts reached consensus that cancer, infection, chronic venous disease, and surgery are risk factors for secondary lymphedema.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for free vascularized lymph node flap transfer (VLNT) and liposuction of bilateral upper extremities (including VLNT with microanastomosis; extensive scar release in axillary region; possible repair of native lymphatics; intraoperative lymphatic mapping of affected limbs; and liposuction of bilateral upper extremities. This patient presents with a history of breast cancer and stage II lymphedema, characterized by gross increase in size of the affected upper extremities due to edema and fibrofatty tissue deposits. The patient’s provider has recommended treatment with VLNT and liposuction.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for complete decongestive therapy with a certified lymphatic therapist for lymphedema treatment consisting of two phases of treatment (Phase I: a) Intensive therapy involving 60 minute sessions for 4-5 days a week for manual lymphatic drainage/massage. b) Adjustments of compression wraps/bandages (enrollee has these items already at home and she brings them to these treatments for adjustments) at each manual lymphatic drainage/massage session. c) Exercise at each manual lymphatic drainage/massage session. d) Skin care at each manual lymphatic drainage/massage session. Phase II: Long term maintenance phase (months or years) involving routine follow up, fitting compression garments to maintain the volume reduction of the effected area achieved in Phase 1 of treatment.).
The patient is a 55-year-old male who presented with severe bilateral leg edema, felt to be a combination of lymphedema and venous insufficiency. A venous duplex study showed no evidence of deep venous obstruction. The patient had not used conservative measures such as leg elevation, compression stockings, or exercise. These measures were prescribed, as well as a pneumatic compression device. The patient did not return to the provider to assess the results of the conservative therapies or the compression device. The patient has requested reimbursement for the cost of the pneumatic compression device. The Health Plan denied his request based on a determination that the device was not medically necessary for the treatment of his venous stasis and lymphedema.Pneumatic compression devices or lymphedema pumps, are considered to be the `last resort` for managing lymphedema.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving lymphedema, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY